Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
about
The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphomaEvaluation of the risks of chemotherapy in dogs with thrombocytopenia.Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).Thymidine kinase assay in canine lymphoma.6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells.Central nervous system relapses in 3 dogs with B-cell lymphoma.Hyperferritinemia is associated with short survival time in dogs with multicentric lymphomaTemozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.Canine lymphoma: a review.Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?Oral melphalan for the treatment of relapsed canine lymphoma.Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.A dexamethasone, melphalan, actinomycin-D and cytarabine chemotherapy protocol as a rescue treatment for feline lymphoma.Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
P2860
Q33413087-3A1D04CB-217E-4114-B904-25EEEBC76450Q33421905-AC7AA34A-7421-4D10-B49A-3F035B21F519Q33426690-79E32ED9-62B2-4074-BA8B-FCDA75944EDCQ33432667-442DA3CC-DC4F-4949-A0F8-2D5C41AE03B6Q34246274-4F96DB75-7950-4E69-95F1-C921E00C4C2AQ34748281-8EC55FAE-E7D0-4835-B38E-252B83C6F61BQ35057461-93960705-E385-4D9A-B5E6-DBD9DB5CE03AQ35924142-D18B8A76-D20E-4064-9680-CBE154F2AC67Q38647190-3B015A5B-7D4A-4ABE-A755-60BBFBE045B5Q38765145-D7FB8F09-F8DA-4C40-BF63-9CEA163A0742Q39593967-A3EBC2CF-2644-41CA-80B4-DCF2DE279178Q40006755-645C3528-F360-42CF-AFFD-1A811FA7947DQ44875615-099D4AFD-1ED9-408A-88A9-E7CC8236981BQ45986875-8F81E0BA-B53F-4060-B00B-91DE7F8D366FQ46147795-E76DCA85-7665-40FA-B015-5A8D0A3E2D48Q46807327-8B84A137-BC56-4253-978A-501F413E7C2EQ48167928-4D487AEF-C235-42D5-BD83-4A7AA98D8B1DQ48359633-91AB966F-094C-457A-8315-60C71FACFB4D
P2860
Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@ast
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@en
type
label
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@ast
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@en
prefLabel
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@ast
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@en
P2093
P1476
Dexamethasone, melphalan, acti ...... r dogs with relapsed lymphoma.
@en
P2093
C Guillermo Couto
Francisco J Alvarez
Stacey L Gallant
William C Kisseberth
P304
P356
10.1111/J.1939-1676.2006.TB00719.X
P577
2006-09-01T00:00:00Z